The 50 fastest growing pharmaceutical products (calculated by subtracting 2014 sales from 2015 sales) generated combined year-on-year growth of $41 billion in 2015.
Gilead Sciences' hepatitis C treatment Harvoni accounted for 29 percent of this figure, with incremental growth of $11.7 billion.
Eight products delivered incremental growth in excess of $1 billion in 2015, three of which were hepatitis C drugs. All of these products were launched in 2014.
The 10 fastest growing pharmaceutical products generated combined growth of $23 billion, equal to 56 percent of growth generated by the 50 drugs included on the list below.
AbbVie's Humira and Pfizer's Prevnar are listed among the industry's 10 fastest growing products in 2015 and among the 10 biggest selling products (Humira remained the biggest selling drug in 2015 with sales of $14 billion). Celgene's Revlimid falls just short of this distinction in terms of incremental growth generated in 2015.
|The 50 biggest growing drugs in 2015|
|Drug||Company||Indication/drug type||2015 sales growth ($m)|
|Prevnar||Pfizer||Streptococcus pneumoniae (vaccine)||1781|
|Eylea||Regeneron||Age-related macular degeneration||940|
|Eylea||Bayer||Age-related macular degeneration||520|
|Keytruda||Merck & Co.||Melanoma/NSCLC||511|
|Esbriet||Roche||Idiopathic pulmonary fibrosis||468|
|Soliris||Alexion||Paroxysmal nocturnal hemoglobinuria||356|
|Opsumit||Actelion||Pulmonary arterial hypertension||349|
|Ofev||Boehringer Ingelheim||Idiopathic pulmonary fibrosis||339|
|Source: Company reported data *growth based on a 2015 concensus forecast|
See also - The 100 best selling pharmaceutical brands in 2015 
Among the 20 fastest growing pharmaceutical products in 2015 are a number of notable new drug launches – in addition to the aforementioned hepatitis C therapies. GlaxoSmithKline's combination HIV therapy Triumeq was launched in 2014 and generated incremental growth of $1 billion in 2015, while Bristol-Myers Squibb's PD-1 inhibitor Opdivo was launched in late 2014 (generating sales of just $6 million that year) and saw revenues swell to $942 million in 2015. Pfizer's breast cancer treatment was launched in early 2015 but recorded impressive sales of $723 million last year to position it 13th on the list.
Roche markets five of the 50 fastest growing pharmaceuticals in 2015, with combined incremental growth of $1.9 billion, while Johnson & Johnson markets four ($2 billion).
Bristol-Myers Squibb ($3.4 billion), AbbVie ($3.3 billion), Novo Nordisk ($1.8 billion), GlaxoSmithKline ($1.8 billion), Celgene ($1.5 billion) and Biogen ($1.3 billion) are each responsible for marketing three drugs included in the list. Gilead, which markets two of the drugs, generates the most incremental revenue ($12.4 billion) due to the performance of the Harvoni franchise.
Among the industry's biggest growing drugs in 2015, hepatitis C therapies delivered incremental growth of $14.7 billion versus the previous year, while oncology treatments delivered $6.5 billion. Despite an increasingly pressured US payer environment, diabetes drugs on the list delivered incremental growth of $2.8 billion, with anticoagulants, autoimmune therapies and HIV drugs each contributing growth of $2.1 billion.